Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Jorge J. Castillo(Dana-Farber Cancer Institute), Steven P. Treon(Dana-Farber Cancer Institute), Lakshmi Nayak(Dana-Farber Cancer Institute), Christian Buske(University Hospital Ulm), Constantine S. Tam(The Alfred Hospital), David Simpson(North Shore Hospital), Gilad Itchaki(Meir Medical Center), Dipti Talaulikar(Australian National University), Samar Issa(Middlemore Hospital), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Toby A. Eyre(Oxford University Hospitals NHS Trust), Kenneth H. Shain(Moffitt Cancer Center), Stephen M. Ansell(Mayo Clinic), Oren Pasvolsky(The University of Texas MD Anderson Cancer Center), Marzia Varettoni(Policlinico San Matteo Fondazione), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Julio C. Chávez(Moffitt Cancer Center), Jonas Paludo(WinnMed)
Cited by 100
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k